Secondary analysis of a trial in 547 patients with a HeartMate 3 LVAD: background drugs did not modify aspirin's effect on haemocompatibility events; RAAS inhibitor use was linked to non-significantly better 12-month event-free survival (78.9% vs 69.3%).
Secondary analysisn = 547
Katz et al. Hemocompatibility Outcomes With Pharmacological Therapy Following LVAD Implantation: Insights From the ARIES-HM3 Trial